New APOC3 loss-of-function data support apoCIII as a treatment target for CV disease prevention

Newly published data on the postprandial kinetics of apoB48 and B100 in chylomicrons, VLDL₁, VLDL₂, IDL and LDL, in people heterozygous for a loss-of-function (LOF) mutation in the APOC3 gene, indicate the potential benefits of apoCIII lowering for cardiovascular disease (CVD) prevention.¹ First author of the paper in JCI Insight, Professor Marja-Riitta Taskinen (Faculty of Medicine, University of Helsinki, Finland), describes the new findings in relation to previous research and the role of apoCIII as a treatment target.